Pelthos Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Cash and cash equivalents | $14,203 | $513 |
| Restricted cash, current | 50 | — |
| Accounts receivable, net | 7,988 | — |
| Inventory, net | 24,096 | — |
| Prepaid expenses and other current assets | 3,424 | 856 |
| Total current assets | 49,761 | 1,369 |
| Property and equipment, net | 10,174 | — |
| Operating lease right-of-use assets, net | 3,352 | — |
| Intangible assets, net | 32,521 | — |
| Goodwill | 30,625 | — |
| Total assets | $126,433 | $1,369 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Accounts payable | $5,666 | $1,897 |
| Accrued expenses | 11,890 | — |
| Operating lease liabilities, current portion | 631 | — |
| Deferred revenue, current portion | 1,019 | — |
| Loan payable, net of debt discount | — | 2,054 |
| Loan payable - related party, net of debt discount | — | 132 |
| Other liabilities | 5,562 | — |
| Total current liabilities | 24,768 | 4,083 |
| Operating lease liabilities, net of current portion | 2,849 | — |
| Deferred revenue, net of current portion | 1,522 | — |
| Deferred income tax liability | 12,866 | — |
| Other long-term liabilities | 26,175 | — |
| Total liabilities | 68,180 | 4,083 |
| Commitments and contingencies (Note 11) | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Preferred stock Series A, $0.0001 par value, 150,000 shares authorized, 57,568 shares issued and outstanding as of September 30, 2025 and 700,000 shares authorized, no shares issued or outstanding as of December 31, 2024, respectively | — | — |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 3,090,729 and 610,389 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid in capital | 101,383 | 18,761 |
| Accumulated deficit | (43,130) | (21,475) |
| Total stockholders’ equity (deficit) | 58,253 | (2,714) |
| Total liabilities and stockholders’ equity (deficit) | $126,433 | $1,369 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.